Code
01J02711
Duration
01 May 2010 → 28 February 2015
Funding
Regional and community funding: Special Research Fund
Promotor
Research disciplines
-
Natural sciences
- Animal biology
-
Medical and health sciences
- Endocrinology and metabolic diseases
- Medical imaging and therapy
- Endocrinology and metabolic diseases
- Medical imaging and therapy
- Endocrinology and metabolic diseases
- Medical imaging and therapy
-
Agricultural and food sciences
- Veterinary medicine
- Other veterinary sciences
- Other agricultural, veterinary and food sciences
Keywords
rhTSH
radioiodine
thyroid
tyrosine kinase inhibitor
cyclooxygenase-2 inhibitor
Project description
64 dogs with CTT are included in three clinical trials. Firstly, we will determine the effectiveness of cyclooxygenase-2 inhibitor (Piroxicam) and tyrosine kinase inhibitor (Toceranib Phosphate) in CTT treatment. Secondly, we will determine the best dosage, route and timing of rhTSH (recombinant-human-thyroid-stimulating-hormone) for radioiodine-131 treatment optimization. Thirdly, we will evaluate the effectiveness of rhTSH in the radioiodine-131 treatment of CTT.